REPLIGEN CORP Contract with Customer, Receivable, after Allowance for Credit Loss
REPLIGEN CORP (RGEN) had Contract with Customer, Receivable, after Allowance for Credit Loss of $157.71 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes
us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss · last filed 2026-07-29
- 2026-06-30: Contract with Customer, Receivable, after Allowance for Credit Loss $157.71M.
- 2026-03-31: Contract with Customer, Receivable, after Allowance for Credit Loss $151.55M.
- 2025-12-31: Contract with Customer, Receivable, after Allowance for Credit Loss $158.59M.
- 2025-09-30: Contract with Customer, Receivable, after Allowance for Credit Loss $148.97M.
| Period end | Contract with Customer, Receivable, after Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $157.71M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $151.55M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $158.59M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $148.97M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $156.95M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $147.41M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $134.12M 10-K · filed 2026-02-26 |
| 2024-09-30 | $129.03M 10-Q · filed 2024-11-18 |
| 2024-06-30 | $123.25M 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $115.77M 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $124.16M 10-K · filed 2025-03-14 |
| 2023-09-30 | $106.16M 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | $120.30M 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $133.49M 10-Q/A · filed 2024-11-18 |
| 2022-12-31 | $116.25M 10-Q/A · filed 2024-11-18 |
| 2022-09-30 | $117.64M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $121.05M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $122.44M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $117.42M 10-K · filed 2023-02-22 |
| 2020-12-31 | $71.26M 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |